Pralsetinib for the treatment of non-small cell lung cancer
| Autor: | Zhe-Sheng Chen, Leli Zeng, X.-Y. Fu, Xing-Duo Dong, Chao Cheng, Charles R. Ashby |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Lung Neoplasms
endocrine system diseases Pyridines non-small cell lung cancer (NSCLC) Carcinoma Non-Small-Cell Lung Medicine Humans Pharmacology (medical) In patient Lung cancer neoplasms Pharmacology business.industry Proto-Oncogene Proteins c-ret Cancer General Medicine medicine.disease respiratory tract diseases Pyrimidines Toxicity Cancer research Adenocarcinoma Pyrazoles Non small cell business Tyrosine kinase |
| Zdroj: | Drugs of today (Barcelona, Spain : 1998). 57(9) |
| ISSN: | 1699-3993 |
| Popis: | The identification of oncogenic drivers and the subsequent development of targeted therapies have been established as biomarker-based care for metastatic non-small cell lung cancer (NSCLC) patients. Rearranged during transfection (RET) events have been reported to be oncogenic drivers in NSCLC and were more common in patients who i) were young; ii) had adenocarcinoma histology; and iii) had never smoked. Phase II studies indicated the limited efficacy of multi-targeted tyrosine kinase inhibitors in patients with NSCLC that have a confirmed RET event. Consequently, there has been ongoing research to develop more potent and specific RET tyrosine kinase inhibitors. Recently, a novel and specific RET inhibitor, pralsetinib (BLU-667), has been reported to have excellent efficacy and low off-target toxicity in RET cancer patients. In this review, we summarize the clinical data regarding the use of pralsetinib in NSCLC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|